PAVmed raises $45 million, eliminates convertible securities overhang
Get Alerts PAVM Hot Sheet
Join SI Premium – FREE
PAVmed Inc. (NASDAQ: PAVM) completed preferred stock and senior secured note financings totaling $45 million in gross proceeds, using the funds to eliminate all previously outstanding convertible securities.
The medical technology company issued $30 million of Series D Convertible Preferred Stock with associated warrants exercisable for up to an additional $30 million upon publication of a positive Medicare local coverage determination for its EsoGuard test. The company also issued a $15 million senior secured note with a February 2029 maturity.
PAVmed used $22.3 million in cash and the $15 million note to redeem all outstanding Series C Convertible Preferred Stock and retire convertible debt. The transactions yielded approximately $7.7 million in net cash proceeds for working capital.
The Series D Preferred Stock conversion into common stock requires stockholder approval at a special meeting scheduled no later than April 30, 2026. The conversion price is set at $6.50 per share. PAVmed has secured voting agreements from stockholders representing approximately 25% of outstanding common stock supporting the conversion.
If warrants are exercised and preferred stock converts upon shareholder approval, the financings would add approximately $37.7 million in cash to the balance sheet and create a capital structure consisting entirely of common stock and long-term debt.
PAVmed operates in medical devices, diagnostics, and digital health sectors through subsidiaries including Lucid Diagnostics Inc. (NASDAQ: LUCD) and Veris Health Inc. The company holds 31 million shares of Lucid common stock on its balance sheet.
The financing was conducted by existing long-term investors, according to the company's press release statement.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bionano Genomics names Alex Hastie as chief scientific officer
- LENZ Therapeutics licenses VIZZ eye drop to Arrotex for Australia, NZ
- Esquire Financial gets stockholder approval to acquire Signature Bank
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share